Key takeaways:
Ozempic (semaglutide) and Jardiance (empagliflozin) are Type 2 diabetes medications. Ozempic is a once-weekly injection approved only for adults. Jardiance is a once-daily oral pill that can be taken by people ages 10 and older.
Ozempic has cardiovascular benefits for people with both diabetes and heart disease. Jardiance has cardiovascular benefits, too. But it’s also approved for heart failure and chronic kidney disease (CKD). Ozempic is being studied for CKD.
Your best option depends on your health history, treatment goals, and risk factors. A healthcare professional might prescribe Ozempic and Jardiance together.
Save on related medications
When it comes to managing Type 2 diabetes, there’s no one-size-fits-all solution. Most people focus on lowering blood glucose (sugar) levels. But some might also need to manage risk factors or related health conditions. And depending on your needs, certain medications may be a better fit than others.
Ozempic (semaglutide) and Jardiance (empagliflozin) are two diabetes medications to consider. They have a few things in common, including cardiovascular benefits for certain people. But there are specific reasons why you might take one over the other — or both. We discuss six key differences between Ozempic and Jardiance below.
1. Ozempic and Jardiance come in different dosage forms
One of the most obvious differences between Ozempic and Jardiance is how you take them. Ozempic is an injection that you administer once a week. Jardiance is an oral pill that you take every day.
Jardiance is also available in several combination pills. These include Synjardy and Synjardy XR with metformin, Glyxambi with linagliptin, and Trijardy XR with metformin and linagliptin.
Ozempic isn’t available in a combination injection, but this may change. Instead, its active ingredient, semaglutide, is available in an oral pill called Rybelsus. Depending on your dose, Rybelsus may be an Ozempic alternative if you don’t like injections.
2. Ozempic and Jardiance work differently for Type 2 diabetes
Ozempic and Jardiance are also different in how they work to manage blood glucose levels.
Ozempic is a glucagon-like peptide-1 (GLP-1) agonist. It simulates the effects of GLP-1, which is a gut hormone. It triggers insulin release after you eat and reduces glucose production in the liver. It also keeps food in your stomach longer. Additionally, Ozempic works on areas of the brain that regulate appetite and fullness.
Jardiance is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. It prevents your kidneys from reabsorbing glucose so that it leaves the body in your urine. Jardiance also has this effect on sodium, which may help lower blood pressure.
Does the difference in how Ozempic and Jardiance work affect blood glucose levels? The short answer: Yes. Ozempic can provide greater reductions in hemoglobin A1C (HbA1c or A1C). Ozempic has been shown to lower A1C by about 2%, depending on the dose. Jardiance lowers A1C by about 1%.
3. Jardiance is approved for adults and children, while Ozempic is approved only for adults
Jardiance is one of two oral medications approved for Type 2 diabetes in children. The other is metformin. Jardiance is approved for people as young as 10 years old.
Ozempic is approved only for adults. But several other GLP-1 agonists are approved for use in children. These include Victoza (liraglutide), Trulicity (dulaglutide), and Bydureon BCise (exenatide).
Metformin is a good starting point for most children. A healthcare professional may add a GLP-1 agonist and/or Jardiance if they need more help lowering their blood glucose levels. In some situations, insulin may be recommended.
4. Ozempic can result in greater weight loss than Jardiance
For many people with Type 2 diabetes, losing even a small amount of weight makes blood glucose levels easier to manage. And if chronic weight management is part of your diabetes treatment plan, Ozempic is often more beneficial than Jardiance.
For people with Type 2 diabetes, Ozempic is commonly prescribed because of its effect on body weight. During a 40-week trial, people who received the highest Ozempic dose (2 mg) lost 15 lbs, on average. Some report losing even more weight.
Jardiance can cause weight loss too. But this tends to be about 4 lbs to 6 lbs after 6 months. One study reported about 12 lbs of weight loss when Jardiance was paired with dietary changes, compared with almost 5 lbs of weight loss without dietary changes.
For either medication, it works best when paired with a diabetes diet and regular exercise. Keep in mind that weight loss can vary by factors such as dose and other medications you’re taking.
5. Jardiance is also approved for heart failure and chronic kidney disease
Ozempic and Jardiance have cardiovascular benefits for people with diabetes and heart disease. But Jardiance is also approved to treat heart failure and chronic kidney disease (CKD) in people with and without diabetes.
Jardiance is one of two SGLT2 inhibitors approved to treat the two most common types of heart failure. The other is Farxiga (dapagliflozin). If you have heart failure, Jardiance can help keep you out of the hospital and lower the risk of cardiovascular death.
Jardiance is also approved for CKD. It can help slow down your kidneys from getting worse and lower the risk of end-stage kidney disease, hospitalization, and cardiovascular death. About 1 in 3 people with diabetes develops CKD. In this case, Jardiance can be a good addition. But it may not lower your blood glucose as well if you have severe CKD.
Ozempic isn’t approved for CKD. But there’s some evidence that it has kidney-related benefits. In fact, Ozempic’s phase 3 CKD study was stopped early because of a high likelihood of success. Study results are expected to be available in the first half of 2024, which could be followed by the FDA approving Ozempic for CKD.
6. Ozempic and Jardiance have different side effects
Another difference between Ozempic and Jardiance are their side effects. Many Ozempic side effects are due to how it affects your gastrointestinal tract. Many Jardiance side effects are from urinating out glucose.
Common Ozempic side effects include nausea and vomiting, diarrhea, and stomach pain. They’re usually worse when you start Ozempic and after increasing your dose. But for many people, they’ll improve over time. Limiting or avoiding certain foods may help in the meantime.
Common Jardiance side effects include urinary tract infections (UTIs) and genital infections. Keep in mind, diabetes increases your risk of UTIs and other infections. Jardiance can also cause increased urination as you pee out more glucose and sodium.
Ozempic and Jardiance may cause serious side effects, but those are less common. With Ozempic, these include pancreatitis, gallbladder disease, and worsening diabetes-related eye problems. There’s also a theoretical risk of thyroid C-cell tumors. With Jardiance, those risks include serious genital infections and ketoacidosis (too much acid in the blood).
The bottom line
Ozempic (semaglutide) and Jardiance (empagliflozin) are Type 2 diabetes medications. Ozempic is a once-weekly injection, and Jardiance is a daily pill. They work differently, resulting in different benefits, uses, and side effects.
Ozempic may cause more weight loss and greater reductions in hemoglobin A1C. Jardiance can be a beneficial addition if you have heart failure or chronic kidney disease. Talk to your healthcare professional for more information.
Why trust our experts?


References
American Diabetes Association. (n.d.). Use of glucose-lowering medications in the management of type 2 diabetes.
American Diabetes Association Professional Practice Committee. (2024). 10. Cardiovascular disease and risk management: Standards of care in diabetes—2024. Diabetes Care.
American Diabetes Association Professional Practice Committee. (2024). 14. Children and adolescents: Standards of care in diabetes—2024. Diabetes Care.
Aviles, B., et al. (2021). MO634 semaglutide in real life practice decreases albuminuria in high risk progression chronic kidney diabetic patients. Nephrology Dialysis Transplantation.
Boehringer Ingelheim Pharmaceuticals Inc. (2023). Jardiance- empagliflozin tablet, film coated [package insert]. DailyMed.
Centers for Disease Control and Prevention. (2022). Diabetes and chronic kidney disease.
Douros, A., et al. (2020). Sodium–glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis. Annals of Internal Medicine.
Feingold, K. R. (2022). Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes. Endotext.
Frías, J. P., et al. (2021). Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): A double-blind, randomised, phase 3B trial. The Lancet: Diabetes & Endocrinology.
Kowalska, K., et al. (2021). Empagliflozin-a new chance for patients with chronic heart failure. Pharmaceuticals.
Novo Nordisk. (2023). Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis.
Sargeant, J. A., et al. (2022). The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial. Diabetes, Obesity, and Metabolism.
Tikkanen, I. (2015). Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care.
U.S. Food and Drug Administration. (2018). FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes.











